Global Vaccine Advancements: Malaria, Mpox, Chikungunya, COVID & More🌍💉
This week’s edition of Vaccine Research Updates brings you cutting-edge developments from across the globe—from Africa’s pioneering malaria rollout to thermostable rabies vaccines and promising sepsis immunotherapies.
🌿 Mali launches the world’s first hybrid malaria vaccination schedule using R21/Matrix-M—targeting both age and seasonality to protect children during peak transmission periods.
🇫🇷 France restricts Valneva’s IXCHIQ® chikungunya vaccine for seniors aged 65 and over after serious adverse events—regulators continue investigations.
🐒 Tonix reports preclinical success with its single-dose TNX-801 mpox vaccine, offering protection even in immunocompromised animals.
🇺🇸 Novavax still awaits full FDA approval for its COVID-19 vaccine as discussions continue on additional trial requirements.
🧊 UK-based Stablepharma begins trials of a tetanus-diphtheria vaccine that withstands extreme temperatures, eliminating the need for cold-chain logistics.
🦇 VitriVax, with CEPI support, is developing a thermostable, single-dose rabies vaccine in collaboration with the Serum Institute of India.
🧬 Longhorn Vaccines showcases broad protection with its sepsis vaccine candidate, LHNVD-303—reducing antibiotic reliance and combatting antimicrobial resistance.
📢 Stay Ahead in Vaccine Research!
✅ Like, share, and subscribe for weekly updates on vaccine research
#VaccineUpdates #GlobalHealth #MalariaVaccine #MpoxVaccine #COVIDVaccine #Chikungunya #RabiesVaccine #SepsisPrevention #ColdChain #BiotechInnovation #LucidQuest #mRNAtechnology #PublicHealth #ClinicalTrials #VaccineBreakthroughs #ThermostableVaccines #PandemicPreparedness #VaccineInnovation #AfricaHealth #CEPI